Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma by Amer Joint Comm Canc Ophthalmic et al.
Multicenter, International Assessment of the Eighth Edition
of the American Joint Committee on Cancer Cancer Staging
Manual for Conjunctival Melanoma
Puneet Jain, MD; Paul T. Finger, MD; Bertil Damato, MD; Sarah E. Coupland, MD, PhD; Heinrich Heimann, MD; Nihal Kenawy, MD; Niels J. Brouwer, MD;
Marina Marinkovic, MD; Sjoerd G. Van Duinen, MD, PhD; Jean Pierre Caujolle, MD; Celia Maschi, MD; Stefan Seregard, MD; David Pelayes, MD;
Martin Folgar, MD; Yacoub A. Yousef, MD; Hatem Krema, MD; Brenda Gallie, MD; Alberto Calle-Vasquez, MD; for the American Joint Committee on Cancer
Ophthalmic Oncology Task Force
IMPORTANCE Eye cancer staging systems used for standardizing patient care and research
need to be validated.
OBJECTIVE To evaluate the accuracy of the eighth edition of the American Joint Committee
on Cancer (AJCC) Cancer Staging Manual in estimating metastatis andmortality rates of
conjunctival melanoma.
DESIGN, SETTING, AND PARTICIPANTS This international, multicenter, registry-based case
series pooled data from 10 ophthalmic oncology centers from 9 countries on 4 continents. A
total of 288 patients diagnosed with conjunctival melanoma from January 1, 2001, to
December 31, 2013, were studied. Data analysis was performed from July 7, 2018, to
September 11, 2018.
INTERVENTIONS Treatments included excision biopsy, cryotherapy, topical chemotherapy,
radiation therapy, enucleation, and exenteration.
MAIN OUTCOMES ANDMEASURES Metastasis rates and 5-year and 10-year Kaplan-Meier
mortality rates according to the clinical T categories and subcategories of the eighth edition
of the AJCC Cancer Staging Manual.
RESULTS A total of 288 eyes from 288 patients (mean [SD] age, 59.7 [16.8] years; 147 [51.0%]
male) with conjunctival melanomawere studied. Clinical primary tumors (cT) were staged at
presentation as cT1 in 218 patients (75.7%), cT2 in 34 (11.8%), cT3 in 15 (5.2%), and cTx in 21
(7.3%). There were no T4 tumors. Pathological T categories (pT) were pTis in 43 patients
(14.9%), pT1 in 169 (58.7%), pT2 in 33 (11.5%), pT3 in 12 (4.2%), and pTx in 31 (10.8%).
Metastasis at presentation was seen in 5 patients (1.7%). Metastasis during follow-up
developed in 24 patients (8.5%) after a median time of 4.3 years (interquartile range, 2.9-6.0
years). Of the 288 patients, 29 died (melanoma-relatedmortality, 10.1%) at a median time of
5.3 years (interquartile range, 1.8-7.0 years). The cumulative rates of mortality among patients
with cT1 tumors were 0% at 1 year, 2.5% (95% CI, 0.7%-7.7%) at 5 years, and 15.2% (95% CI,
8.1%-27.4%) at 10 years of follow-up; among patients with cT2 tumors, 0% at 1 year, 28.6%
(95% CI, 12.9%-58.4%) at 5 years, and 43.6% (95% CI, 19.6%-77.9%) at 10 years of follow-up;
and among patients with cT3 tumors, 21.1% (95% CI, 8.1%-52.7%) at 1 year of follow-up and
31.6% (95% CI, 13.5%-64.9%) at 5 years of follow-up. Patients with cT2 and cT3 tumors had a
significantly higher cumulative mortality rate compared with those presenting with cT1
tumors (log-rank P < .001). Patients with ulceratedmelanomas had significantly higher risk of
mortality (hazard ratio, 7.58; 95% CI, 1.02-56.32; P = .04).
CONCLUSIONS AND RELEVANCE This multicenter, international, collaborative study yielded
evidence that the conjunctival melanoma staging system in the eighth edition of the AJCC
Cancer Staging Manual can be used to accurately estimate metastasis andmortality rates.
These findings appear to support the use of AJCC staging as a tool for patient care and
research.
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C onjunctival melanomas comprise 2% of all ocular tu-mors and 5% of eye melanomas1-3; however, their in-cidence is increasing.4 Tumor-related mortality is re-
ported to be 30%.5 Reliable prognostic tools are needed to
enhance clinical and basic science research.
Published by the American Joint Committee on Cancer
(AJCC) andusedby theUnion for InternationalCancerControl,
the TNM staging system is widely implemented around the
world. In2016, theAJCCOphthalmicOncologyTaskForce cre-
atedtheeightheditionoftheconjunctivalmelanomastagingsys-
tem with data from more than 50 eye cancer specialists in 18
countries.Changes fromtheseventhedition includefurtherde-
fining the tumors’ circumferential extent to define the clinical
T categories.6
Widelyacceptedbymedicaloncology,ophthalmiconcology,
radiation oncology, andmedical journals, theAJCC-TNMstag-
ing system serves to standardize data reporting, case-to-case
prognosis, andselectionof themost suitable treatment for con-
junctivalmelanoma. Specialistswhostage cancershave recog-
nizedtheneedforstandardizedcollaborativedatasharing.7,8We
performed,toourknowledge, thefirstmulticenter, international
study toevaluate theaccuracyof theeightheditionof theAJCC
CancerStagingManual inestimatingmortality ratesofmetasta-
sis from conjunctivalmelanoma.
Methods
Patients diagnosed with conjunctival melanoma from Janu-
ary 1, 2001, to December 31, 2013, were included in this mul-
ticenter, international study. Data were collected retrospec-
tively andentered into a secure onlinedatabase.Data analysis
was performed from July 7, 2018, to September 11, 2018. This
studyadhered to the tenets of theDeclarationofHelsinki9 and
theHealth InsurancePortabilityandAccountabilityActof 1996.
All participating centers obtained internal institutional re-
view board approval to perform retrospectivemedical record
reviews and contribute data to the AJCC Ophthalmic Oncol-
ogy Task Force Conjunctival Melanoma Registry. The Prin-
cess Margaret Cancer Centre determined that individual pa-
tient consentwas not required because therewere no patient
identifiers.
Conjunctival Melanoma Registry Centers
In 2015, at the first Eye CancerWorking Day, held at the Curie
Institute (Paris, France), 158 eye cancer specialists were in-
vitedtoparticipate in thisconjunctivalmelanomaregistry.Con-
ceptualizedasan internet-baseddata-sharing registry, thedata
fieldsweredesignedbyparticipatingeyecancerspecialists.The
resulting registry included data from 10 ophthalmic oncol-
ogy centers in 9 countries (2 in theUnited States and 1 each in
Canada, Colombia, Argentina, France, Netherlands, United
Kingdom, Sweden, and Jordan) on 4 continents (North
America, South America, Europe, and Asia).
Data Security
The following features were incorporated to ensure data se-
curity and study participant privacy. There were no personal
identifiers. The participants were assigned a unique identifi-
cationnumber at their local institution that linkedpatients to
locally stored corresponding identification numbers to en-
sure accuracyof follow-upandoutcomes. SecureSocketLayer
encryptionwasusedtoprevent information frombeingviewed
bythirdparties.Registryaccesswas limitedtoparticipantswith
useraccounts.Therefore, the loginpagerequiredauniqueuser-
nameandpasswordcombination toaccess theapplication.The
database incorporated record locking to prevent different us-
ers fromaccessing the same record for the same studypartici-
pant at the same time. This locking prevented unintentional
overwriting or data corruption. In addition, audit trails were
automatically created. Such logswere stored in a separate, se-
cured directory and were not available online.
Tumor Staging
Clinical (cT) and pathologic (pT) staging were performed ac-
cording to thestagingsystemfor conjunctivalmelanoma in the
eighth edition of the AJCC Cancer Staging Manual6 (Table 1).
According to theAJCC,T1disease is confined to thebulbar con-
junctiva, T2 disease affects the nonbulbar conjunctiva and/or
caruncle, and local invasion to adjacent tissues elevates the
conjunctivalmelanoma toT3disease. T4diseasedenotes cen-
tral nervous system invasion.6
Definitions
Ophthalmic oncology examinations were performed accord-
ing to the standards and practice of each participating center.
These practices included slitlamp and gonioscopic photogra-
phy andhigh-frequency anterior segmentultrasonography to
rule out intra-ocular invasion.Metastaseswere subgroupedat
presentation or during follow-up. Systemic screening forme-
tastasis was performed according to the custom and practice
of the local institutions. Time to death was defined as the in-
terval between date of diagnosis and the date of metastasis.
Becauseat the timeof thestudynocurative treatment formeta-
static conjunctivalmelanomaexisted,metastasis andmortal-
ity were deemed to be equivalent for the study.
Statistical Analysis
Means (SDs)ormedians (interquartile ranges [IQRs])wereused
to express continuous variables, whereas categorical vari-
Key Points
Question Can the eighth edition of the American Joint Committee
on Cancer (AJCC) Cancer Staging Manual for conjunctival
melanoma be used to accurately estimate metastasis and
mortality rates?
Findings In this case series of 288 patients, there was a
significantly higher cumulative mortality rate among patients with
cT2 and cT3 conjunctival melanoma compared with those
presenting with cT1 conjunctival melanoma.
Meaning Higher T-staged tumors were associated with both an
earlier and greater incidence of metastasis; therefore, the results
from this multicenter, international registry study support the use
of the eighth edition AJCC staging system for conjunctival
melanoma.
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ableswereexpressedasproportions.Groupcomparisonswere
made using the t test or Wilcoxon rank sum test for nonpara-
metricvariables.Analysisofvarianceor theKruskal-Wallis test
wasused to comparevariables acrossmore than2groups. The
χ2 test or Fisher exact test was used to analyze group differ-
ences across categorical variables. Separate survival analyses
wereperformedusingmetastasis andmortality as the censor-
ing variable, and Kaplan-Meier curves were plotted to depict
cumulative survival rates at various time points.
Because of the number of patients analyzed in this study,
thedifferent tumor subgroupswere combined intoT1, T2, and
T3 for plottingmeaningful Kaplan-Meier curves. Comparison
between the survival rates of different subgroups was ana-
lyzedusing the log-rank test. The survival probability for each
outcomewas assessedusingCoxproportional hazards regres-
sionmodels and displayed using hazard ratios (HRs). Covari-
ates used for adjusting HRs were those with a P < .10 in uni-
variatemodels and those thatwere associatedwithmortality
in previous studies3,5,7 (tumor location, tumor invasion, ul-
ceration, and lymphatic invasion).
Datawere exported intoMicrosoft Excel (Microsoft Corp)
foranalysis.DatawereanalyzedusingStata,version12.1 (Stata-
Corp) statistical analysis software package, and a 2-tailed
P < .05 was considered to be statistically significant.
Results
Demographics
Atotalof288eyes from288patients (mean[SD]age,59.7 [16.8]
years; range, 15-95 years; 147 [51.0%] male) with conjunctival
melanomawere studied.All patientshad the relevantdata set;
therefore, no patient was excluded from the study. There was
slightpreponderanceofrighteye involvement (n = 154[53.4%]).
The median follow-up time (from the time of definitive treat-
ment) was 4.4 years (IQR, 2.3-6.9 years; range, 1month to 14.3
years).
Clinical Staging
Table 1 gives the AJCC definitions of tumor size, extent, and
pathologiccharacteristicsofconjunctivalmelanoma.Ontheba-
sisof theeightheditionof theAJCCCancerStagingManual, the
clinical T categorieswere cT1 in 218 patients (75.7%), followed
bycT2(34[11.8%]),cT3(15[5.2%[),andcTx(21[7.3%]).Adetailed
analysisofsubgroupsfound117eyes(40.6%)withT1a,63(21.9%)
withT1b,8(2.8%)withT1c,2 (0.7%)withT1d,28(9.7%)withun-
specifiedT1disease,8(2.8%)withT2a,5(1.7%)withT2b,8(2.8%)
withT2c,8(2.8%)withT2d,5(1.7%)withunspecifiedT2disease,
1 (0.7%)withT3a, 10 (3.5%)withT3b, and4 (1.4%)withT3cdis-
ease (Table 2). Therewere no cT4 tumors.
Pathologic Staging
Pathologic T categories according to the eighth edition of the
AJCC Cancer Staging Manual were pTis in 43 (14.9%), pT1 in
169 (58.7%), pT2 in 33 (11.5%), pT3 in 12 (4.2%), and pTx in 31
(10.8%). Subgroup details were as follows: T1a in 123 (42.7%),
T1b in 46 (16.0%), T2a in 12 (4.2%), T2b in 21 (7.3%), T3a in 1
(<0.7%), T3b in 6 (2.1%), and T3c in 5 (1.7%) (Table 2).
Nodes
Nodal status at presentation was N0 in 209 (72.6%) followed
byN1 in 13 (4.5%) andNx in 66 (22.9%). Ipsilateral preauricu-
lar and cervical lymph nodes were reported to be involved in
9 of 13 patients (69.2%), and 4 were uncategorized.
Table 1. Conjunctival Melanoma as Defined by the Eighth Edition
of the American Joint Committee on Cancer Cancer StagingManual
Category Criteria
Clinical Tumor (cT)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor of the bulbar conjunctiva
T1a <1 Quadrant
T1b ≥1 to <2 Quadrants
T1c ≥2 to <3 Quadrants
T1d ≥3 Quadrants
T2 Tumor of the nonbulbar (forniceal, palpebral, and tarsal)
conjunctiva and tumor involving the caruncle
T2a Noncaruncular and ≤1 quadrant of the nonbulbar
conjunctiva involved
T2b Noncaruncular and >1 quadrant of the nonbulbar
conjunctiva involved
T2c Caruncular and ≤1 quadrant of the nonbulbar conjunctiva
involved
T2d Caruncular and >1 quadrant of the nonbulbar conjunctiva
involved
T3 Tumor of any size with local invasion
T3a Globe
T3b Eyelid
T3c Orbit
T3d Nasolacrimal duct and/or lacrimal sac and/or paranasal
sinuses
T4 Tumor of any size with invasion of the central nervous
system
Pathologic Tumor (pT)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Melanoma confined to conjunctival epithelium
T1a Tumor of the bulbar conjunctiva with invasion of the
substantia propria, not >2.0 mm in thickness
T1b Tumor of the bulbar conjunctiva with invasion of the
substantia propria, >2.0 mm in thickness
T2a Tumor of the nonbulbar conjunctiva involved with invasion
of the substantia propria not >2.0 mm in thickness
T2b Tumor of the nonbulbar conjunctiva with invasion of the
substantia propria >2.0 mm in thickness
T3a Globe
T3b Eyelid
T3c Orbit
T3d Nasolacrimal duct, lacrimal sac, and/or paranasal sinuses
T4 Tumor of any size with invasion of the central nervous
system
Regional Lymph Node (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
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Metastasis
Metastasis classification at presentationwasM0 in 216 (75%)
andM1 in 5 (1.7%); for 67patients (23.3%), thesedatawerenot
available. Of the 5 patients withmetastasis, 3 had pulmonary
metastasis (1ofwhomhadsynchronousbone involvement)and
2 had hepatic metastasis. An additional 24 of 283 patients
(8.5%) developedmetastasis during follow-up (median time,
4.3 years; IQR, 2.9-6.0 years). The liver was the most com-
mon site ofmetastasis, found in 11 patients (45.8%), followed
by the lungs in 9 patients (37.5%), brain in 3 (12.5%), bone in 2
(8.3%), and abdomen in 2 (8.3%),with 1 case each in the blad-
der, peritoneum, parotid gland, and skin. Multiorgan metas-
tasiswas seen in 10of the 24patients (41.7%), and sites ofme-
tastasis were not documented in 3 patients (12.5%).
CumulativeMortality Rates According to Clinical Stage
Of the 288 patients, 29 (10.1%) died of conjunctival mela-
noma at a median time of 5.3 years after diagnosis (IQR, 1.8-
7.0 years). The cumulative mortality rates were 0% at 1 year,
2.5% (95%CI, 0.7%-7.7%) at 5 years, and 15.2% (95%CI, 8.1%-
27.4%) at 10 years of follow-up for patientswith cT1 stage dis-
ease;0%at 1 year, 28.6% (95%CI, 12.9%-58.4%) at 5years, and
43.6% (95% CI, 19.6%-77.9%) at 10 years of follow-up for cT2
disease; and 21.1% (95% CI, 8.1%-52.7%) at 1 year and 31.6%
(95%CI, 13.5%-64.9%) at 5 years of follow-up for cT3 disease,
indicating that patients with cT2- and cT3-staged conjuncti-
valmelanomas had a significantly higher cumulativemortal-
ity rate compared with those with cT1 disease (log-rank
P < .001), but themortality rates among cT2, cT3, andTxwere
not significantly different (log-rankP = .13). Cumulativemor-
tality rates of subgroups of cT1, cT2, and cT3disease are given
in Table 2. The Kaplan-Meier comparative survival curves for
cT1, cT2, and cT3 disease are shown in Figure 1.
CumulativeMortality Rates According to Pathologic Stage
The cumulativemortality rateswith respect topathologic cat-
egories andat various timepointswere0%at 1 year, 3.1% (95%
Figure 1. Kaplan-Meier Survival Curves Showing Cumulative Survival
Rates for PatientsWith Different Clinical T Staging
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Table 2. CumulativeMortality Rates Based on American Joint Committee on Cancer Stage Over Time
Category
No. of
Patients
Melanoma-Related
Deaths, No. (%)
Cumulative Mortality, % (95% CI)
1 y 5 y 10 y
Clinical T Categorya
Tx 21 3 (14.3) 0 9.1 (1.3-49.1) NA
T1a 117 9 (7.7) 0 3.5 (0.8-13.3) 20.5 (9.8-40.3)
T1b 63 3 (4.8) 0 1.9 (0.3-13.1) 10.1 (2.1-42.3)
T1c 8 1 (12.5) 0 0 50.0 (9.0-99.4)
T1d 2 0 0 NA NA
T2a 8 0 0 0 NA
T2b 5 2 (40.0) 0 60.0 (17.1-98.8) NA
T2c 8 0 0 0 NA
T2d 8 1 (12.5) 0 0 NA
T3a 1 1 (100) 0 NA NA
T3b 10 2 (20.0) 11.1 (1.6-56.7) 11.1 (1.6-56.7) NA
T3c 4 4 (100) 33.3 (5.5-94.6) 66.7 (22.6-99.1) NA
Pathologic T Category
Tx 31 3 (9.7) 0 0 NA
Tis 43 0 0 0 0
T1a 123 7 (5.7) 0 2.5 (0.6-9.7) 13.9 (6.1-29.9)
T1b 46 3 (6.5) 0 5.0 (0.7-30.5) 5.0 (0.7-30.5)
T2a 12 5 (41.7) 0 32.7 (11.5-72.3) 77.5 (38.5-98.9)
T2b 21 4 (19.0) 0 24.2 (6.3-69.5) 43.2 (15.2-85.5)
T3a 1 1 (100) NA NA NA
T3b 6 2 (33.3) 20.0 (3.0-79.6) NA NA
T3c 5 4 (80.0) 25.0 (3.9-87.2) 50.0 (15.5-94.2) NA
Abbreviation: NA, not applicable.
a Unspecified cT1 disease in 28 (9.7%)
and unspecified cT2 disease in 5
(1.7%).
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CI, 0.9%-9.5%) at 5 years, and 13.6% (95% CI, 6.1%-26.4%) at
10 years of follow-up for eyes with pT1 conjunctival mela-
noma;0%at 1year, 27.2%(95%CI, 11.7%-55.6%)at 5years, and
61.0% (95%CI, 33.4%-89.8%) at 10years of follow-up for pT2;
and 30.0% (95%CI, 10.8%-67.1%) at 1 year and41.7% (95%CI,
17.9%-77.1%) at 5 years for pT3 (Table 2), indicating that pa-
tientswith pT2 and pT3 tumors had a significantly higher cu-
mulativemortality ratecomparedwith thosewithpT1 (log rank
P < .001), but themortality rate forpT2was slightly lower than
that for pT3 (log rank P = .06). No differences were found for
other pairwise group comparisons. The Kaplan-Meier com-
parative survival curves for pT1, pT2, and pT3 are shown in
Figure 2.
On multivariable Cox proportional hazards regression
analysis, patientswith higher cT stages (cT2, cT3) had 3 times
greater risk ofmortality (HR, 3.25; 95%CI, 1.48-7.11;P = .003)
comparedwiththosewithcT1.Patientswithconjunctivalmela-
nomas reported to have ulceration at presentation also had a
significantly higher risk of mortality (hazard ratio, 7.58; 95%
CI, 1.02-56.32;P = .04) (Table 3). This study alsonotes that in-
volvementof theplica, caruncle, and lymphatic invasion likely
didnot influencemortality rates.Althoughcaruncular andpli-
cal involvement were not a significant risk factor for metas-
tasis, there were 15 T3-staged tumors (4.5%).10
Discussion
Multicenter, international tumor registries are providing new
medical evidencebyallowinganalysis of largenumbersof rare
tumors.2,5,7,8,11-14Thisregistryprovidedevidencefromalargecase
seriesofeyeswithconjunctivalmelanoma.Thefindingssuggest
that the eighth edition of AJCCCancer StagingManual for con-
junctivalmelanoma is valid. Specifically, the rates of 1-, 5-, and
10-yearmortality increasedwith the advancing initial cT stage
of theprimary tumor.Thestudyalso revealed independent fac-
torsassociatedwith increasedmortality,which includedtumor
thickness, tumor invasion, andulceration (Table3).Caruncular
or plical involvement did not affectmortality.
The finding that the cumulative rate ofmortality with re-
spect toclinical categoriesshowedasteep increase fromT1 (3%)
toT2 (28%) at the 5-year follow-up suggests the validity of the
staging system.This increase inmortality supports the impor-
tance of tumor location, with nonbulbar tumors (T2) tending
to bemore aggressive or harder to control than bulbar tumors
(T1). The cumulative 10-year mortality was 3-fold greater for
T2 disease compared with T1 disease (43.6% vs 15.2%). Pa-
tients with T3 disease were the only ones with mortality at 1
year (cumulative mortality rate of 21%). The 5-year cumula-
tivemortality rateswere comparable for patientswith T2 and
T3 tumors.However, on subgroupanalysis, thenumber of pa-
tients in the T3 group was insufficient for 5-year analysis. Al-
though there are no multicenter data on cumulative mortal-
ity rates to date, previous single-center studies2,3,5,7,13,14 have
suggested that larger tumors are associated with a higher in-
cidence ofmetastasis andmortality. All patients inwhompri-
mary tumor could not be assessed (ie, cTx and pTx catego-
ries) were censored for the calculation of mortality rates.
In this study, the cumulativemortality rateswere compa-
rable for both clinical andpathologic T categories,which sug-
gests that clinical staging is at least asuseful aspathologic stag-
ing for mortality. Univariate and multivariable HR analyses
revealed trends that were comparable to previous studies
(Table 3).2,7,10,13-17 However, contrary to the AJCC definitions
andprior studies,10,12,15 our data analysis didnot support con-
junctival melanoma involvement of the plica and caruncle
being associated with higher mortality rates. A small case se-
ries suggested that, like other mucous membrane melano-
mas, immunotherapymaybe effective in the treatment of ad-
vanced local and metastatic conjunctival melanoma.18,19
This study supports the continued use of the conjuncti-
valmelanoma staging system published in the eighth edition
of the AJCC Cancer Staging Manual because use of the tool
helpedtoaccuratelyestimatemelanoma-relatedmortality.The
study suggests a potential formodificationofweightingof ca-
runcular andplical involvement aswell asT4definitions.Uni-
versal staging allowed for largemulticenter, international co-
operation investigating a rare ophthalmic cancer. This study
provideddata analysis to improve our knowledge of conjunc-
tival melanoma.
Limitations
The main limitation of this study is its retrospective design.
Another limitation is the small number of patients in some cT
categories; 75.7%of the tumorswerecT1staged,andtherewere
no cT4 tumors. Because there were no criteria for case selec-
tion, this distribution represents the clinical experienceof the
multiple international centers involved in this study. Ethnic/
racial backgrounds were not collected as data; however, be-
cause thedatawerederived from4continents, the registry in-
cluded a broad spectrum of patients. In contrast, Zhou et al13
reported on mostly cT2 and cT3 tumors from the Chinese
population.5,7
Figure 2. Kaplan-Meier Survival Curves Showing Cumulative Survival
Rates for PatientsWith Different Pathological T Staging
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Conclusions
These results suggest that the conjunctival melanoma stag-
ing system in the eighth edition of AJCC Cancer Stag-
ing Manual can be used to accurately estimate mortality
related to metastatic disease. The findings also suggest that
international, multicenter, registry-based studies of
rare cancers can be performed using internet-based data
sharing.
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